About MayMag Biologics
Redefining the US Biosimilar Supply Chain
Formerly Zeptide Pharma / Tirzepatide Pharma — rebranding as MayMag Biologics effective Q1 2027
Our Story
MayMag Biologics, previously known as Tirzepatide Pharma (and operating under the name Zeptide Pharma), was founded with a single conviction: the United States should never again face a biosimilar shortage because of fragile overseas supply chains.
We built our operations from the ground up as a 506(e) industrial pharmaceutical manufacturer — not a retail 503b compounder — focused exclusively on large-scale production of FDA-shortlisted generic drugs and biosimilar biologics for commercial distributors.
Today we rank as the No. 5 top insulin pen manufacturer in the USA, with multiple FDA-compliant, GMP-certified facilities covering both active drug substance synthesis and fill-finish final steps. Our rebrand to MayMag Biologics in Q1 2027 marks the next chapter of that mission.
Our Mission
To eliminate biosimilar supply chain vulnerability for US commercial distributors by delivering domestic, GMP-certified, large-scale manufacturing with zero tolerance for backorders.
Domestic Reliability
US-based facilities mean drug quality is controlled and monitored under FDA oversight — no overseas logistics risk.
Scale Without Compromise
Facility redundancy and device supply chain depth to meet 100% of market demand without a single day of backorder.
Regulatory Excellence
Clean FDA Form 483 records, zero warning letters, cGMP compliant, ISO 13485 certified, and USP <797> <800> compliant.
Stability Expertise
Deep formulation-through-transportation know-how to handle large-batch stability requirements without product degradation.
Areas of Expertise
Insulin Pen Manufacturing
Ranked No. 5 insulin pen manufacturer in the USA. In-house 510k auto device pen manufacturing with full device continuity assurance.
GLP-1 Biosimilars
Tirzepatide, Semaglutide, Cagrillintide, and Retatrutide — active drug substance and fill-finish under one roof.
Sterile Injectables & Bac-Water
WFI-grade bacteriostatic water for injection, Epinephrine pens, and rheumatoid arthritis auto-injectors at commercial scale.
Inhalation Therapeutics
MDI, DPI, and SMI inhalation medicine manufacturing — innovative biotechnology solutions for respiratory drug delivery.
CDMO Services
Contract development and manufacturing for FDA-shortlisted drugs, from custom peptide synthesis to industrial-scale fill-finish.
Quality Systems
Eight-step quality control framework covering raw material testing, in-process checks, and final release — every batch, every time.
Regulatory Credentials
- 506(e) Industrial Manufacturer
- FDA-Registered Outsourcing Facility
- cGMP Compliant
- ISO 13485 Certified
- USP <797> & <800> Compliant
- Clean FDA Form 483 Records
- Zero Warning Letters
- 510k Auto Device Pen Manufacturing
Ready to secure your supply chain?
Contact our team to validate our FDA credentials and discuss how MayMag Biologics can become your domestic biosimilar manufacturing partner.
Partner with us